You are here

Study finds 4 drugs have little to no effect on COVID-19--WHO

Primary tabs

GENEVA (AP) — The world’s largest randomized trial of COVID-19 treatments found “conclusive evidence” that remdesivir, a drug used to treat U.S. President Donald Trump when he fell ill, has little or no effect on severe cases, the U.N. health agency said Friday.

The World Health Organization announced the long-awaited results of a six-month trial that endeavored to see if existing drugs might have an effect on the coronavirus.

The study, which was not peer-reviewed, found that four treatments tested — remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon — had “ little or no effect” on whether or not patients died within about a month or whether hospitalized patients recovered.

Most of those had already been ruled out. But remdesivir, an antiviral, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU. Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.

The results of the global trial are in sharp contrast to a large study in the United States, which found remdesivir shortened the time to recovery by about five days on average.

Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” he said in a statement. He said the drug is now recommended in some countries but there have been significant concerns about supply, cost and access. ...tments.”

The treatments given to President Trump after he tested positive for the coronavirus included remdesivir. ...

Problem, Solution, SitRep, or ?: 
Groups this Group Post belongs to: 

Comments

....other scientists said the design of the W.H.O.’s sprawling clinical trial, which collected data from hundreds of hospitals, meant the conclusions were not definitive.

Conducted in dozens of countries with various health care systems and inconsistent treatment protocols, the data are difficult to analyze and compare, said Dr. Peter Chin-Hong, an infectious disease expert at the University of California, San Francisco. ...

howdy folks
Page loaded in 0.547 seconds.